Pep1-AGL

Discontinued Product

Pep1-AGL (Cat. No. 1602) has been withdrawn from sale for commercial reasons.
Description: GluA1 subunit C-terminus peptide analog; also analog of Pep1-TGL (Cat. No. 1601)
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for Pep1-AGL

Pep1-AGL is an analog of Pep1-TGL (Cat. No. 1601), a peptide containing the 'TGL' motif that corresponds to the C-terminus of the AMPA receptor GluA1 subunit.

Technical Data for Pep1-AGL

M. Wt 960.11
Formula C40H69N11O14S
Sequence SSGMPLGAAGL
Storage Desiccate at -20°C
PubChem ID 90479812
InChI Key DKRJFJKDHRZRQJ-PJYAFMLMSA-N
Smiles [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for Pep1-AGL

References are publications that support the biological activity of the product.

Hayashi et al (2000) Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 287 2262 PMID: 10731148

Shi et al (2001) Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons. Cell 105 331 PMID: 11348590

View Related Products by Target

Keywords: Pep1-AGL, Pep1-AGL supplier, Analog, Glutamate, AMPA, Receptors, iGluR, Ionotropic, GluA1, GluR1, 1602, Tocris Bioscience

Citations for Pep1-AGL

Citations are publications that use Tocris products.

Currently there are no citations for Pep1-AGL.

Reviews for Pep1-AGL

There are currently no reviews for this product. Be the first to review Pep1-AGL and earn rewards!

Have you used Pep1-AGL?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.